HLHui Liu

Hui Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Liu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Chenchen Wang

    Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, P. R. China

    2 shared publications
  • Genyan Liu

    Wuhan Institute of Technology

    2 shared publications
  • Na Zhai

    Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, P. R. China

    2 shared publications
  • Xiulian Ju

    Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, P. R. China

    2 shared publications
  • Dedong Cao

    Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China

    1 shared publication
  • Fengshou Wu

    Hubei Key Laboratory of Novel Reactor and Green Chemical Technology Key Laboratory for Green Chemical Process of Ministry of Education School of Chemical Engineering and Pharmacy Wuhan Institute of Technology Wuhan 430205 Hubei P. R. China

    1 shared publication

Latest Publications

  • Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma

    by Xiaohong Liu, Dedong Cao, Hui Liu, XiaoKang Ke, Xin Liu, Ximing Xu

    Objective Nasal or extranasal natural killer/T-cell lymphoma (NKTCL) is a very rare aggressive lymphoma, but it is increasingly diagnosed. To evaluate some specificity by comparative analysis between primary upper aerodigestive tract (UAT) and non-upper aerodigestive tract (NUAT)NKTCL. Methods A retrospective analysis was performed on NKTCL patients from January 2013 to November 2022 in our cancer center. Results The majority of the lesions were UAT-NKTCL 70 cases (92.1%), the primary NUAT occurred in 6 cases. Patients in the UAT group were mainly in the early stage and in the low and medium risk, while those in the NUAT group were late stage and in high risk (p = 0.000). The expressions of CD3 and TIA-1 in UAT group were higher than those in NUAT group (p = 0.031, p = 0.003), while CD7 was dominant in NUAT group (p = 0.009). For early stage NKTCL, multivariate analysis suggested that gender and PINK score were independent factors affecting PFS and OS (p < 0.05). The 3 year OS rate in initial CR group was 90.1% versus 46.4% in non-CR group (p = 0.000). In advanced stage, KI67% and bone marrow involvement were independent factors affecting OS (p = 0.022, p = 0.038). Conclusion It was difficult to distinguish between UAT and NUAT-NKTCL from histopathology. NUAT-NKTCL patients did have advanced stage and poor outcome. The prognostic value of PINK score and bone marrow involvement was proposed. We aimed to improve initial CR rates, as well as to find new predictive models to predict the whole population.


  • A multiscale screening strategy for the identification of novel xanthine oxidase inhibitors based on the pharmacological features of febuxostat analogues

    by Na Zhai, Yanming Chen, Chenchen Wang, Fengshou Wu, Xiaogang Luo, Xiulian Ju, Hui Liu, Genyan Liu

    Hyperuricemia (HUA), an abnormally high level of uric acid (UA) in the blood, is showing an increasing incidence and younger tendency worldwide. Xanthine oxidase (XO) inhibitors (XOIs) can reduce the UA production by inhibiting the XO activity, which has been considered as a promising strategy for HUA treatment. In this study, pharmacophore models were first established to extract the key features of potent XOIs, including febuxostat and topiroxostat. Multiple virtual screening was then carried out based on the best pharmacophore model, and 4 hits (N1–4) with satisfactory pharmacokinetic parameters by prediction and ideal docking modes were retrieved from the ZINC database. The 4 protein–hit complexes were then subjected to 50 ns molecular dynamics (MD), which verified the stability of these hits in the XO binding pocket. The binding free energies revealed that hits N3 and N4 might possess better stability and higher affinity with XO. The residue-based energy contribution indicated that some key residues, including Asn768, Lys771, Glu802, Arg880, Phe914, Phe1009, and Thr1010, could affect the binding of compounds with XO through hydrogen bonds, π–π stacking, and hydrophobic interactions. These results might provide helpful information for the design and development of novel XOIs.


  • Exploration of Novel Hepatitis B Virus Capsid Assembly Modulators by Integrated Molecular Simulations

    by Chenchen Wang, Na Zhai, Yilan Zhao, Fengshou Wu, Xiaogang Luo, Xiulian Ju, Genyan Liu, Hui Liu

    Capsid protein (Cp) plays an important role in the entire life cycle of Hepatitis B Virus (HBV) and is considered as a novel anti‐HBV target. A series of novel sulfamoylbenzamide (SBA) derivatives have been recently identified as HBV capsid assembly modulators (CAMs) with EC 50 values at a low micromolar range. In this study, ligand‐ and receptor‐based molecular simulations were performed to understand the structure‐activity relationships (SARs) and the interaction mechanisms of these novel HBV CAMs. The constructed three‐dimensional quantitative SAR (3D‐QSAR) models exhibited good predictive abilities and well explained the SARs of these novel CAMs. Docking results suggested that HBV Cp TRP102 and THR128 might be key residues, which could form significant hydrogen bonds with these CAMs. Molecular dynamics (MD) results indicated that the most potent CAM could stably bind to the HBV Cp dimer or hexamer rather than the monomer, indicating that the inter‐dimer interface might be important for SBA CAMs to stably bind with HBV Cp. Furthermore, five novel hit compounds ( N1 ‐ 5 ) as HBV CAMs were screened out by a comprehensive virtual screening. Compounds N1 and N2 were proved to bind well with the HBV Cp dimer and hexamer by MD simulations, and might have stronger interactions with the protein than the most potent SBA. These results might provide advantageous enlightenments for designing and developing novel HBV CAMs.